NCT00646542View on ClinicalTrials.gov

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

PHASE3CompletedINTERVENTIONAL
Enrollment

525

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2010

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Vildagliptin

DRUG

Placebo

Trial Locations (12)

Unknown

Buenos Aires

Heidelberg Heights

Winnipeg

Cartago

Tampere

Angers

Dormagen

Chennai

Oslo

Saint Petersburg

Alicante

Lund

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY